| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 28(3); 1996 > Article
Journal of the Korean Cancer Association 1996;28(3): 582-589.
고용량의 Cisplatin 병합화학요법시 급성 진토효과에 대한 Granisetron 과 Metoclopramide , Dexamethasone , Lorazepam 병용요법의 비교
신원용, 박성규, 전진우, 원종호, 백승호, 오도연, 홍대식, 박희숙
A Comparison of the Acute Antiemetic Effect of Granisetron with Combination of Metoclopramide , Dexamethasone and Lorazepam in Patients Receiving High
Won Yong Shin, Seong Gyu Park, Jin Woo Jeon, Jong Ho Won, Seung Ho Baik, Dae Sik Hong, Dae Sik Hong, Hee Sook Park
Granisetron, a 5-hydroxytryptamine3(5-HT3) receptor antagonist, is effective antiemetic agent in the control of cisplatin-induced emesis. We compared the efficacy and safety of granisetron with those of intravenous high-dose metoclopramide(1.5 mg/kg, four times) plus dexamethasone(10 mg i.v.) and lorazepam(2 mg i.v.)(MDL therapy) to control the acute emesis induced by high-dose cisplatin(>60mg/§³) treatment. Granisetron was injected in dose of 3 mg intravenously as recommended schedule for the prophylaxis of acute cisplatin-induced emesis. Granisetron was effective as MDL therapy for controlling of acute emesis. Of 25 granisetron-treated patients, 18(72%) were complete or major responders compared with 19/25(76%) patients who recieved the MDL therapy on first day of chemotherapy(P> 0.05). Also, in controlling of nausea, granisetron results were similar to MDL therapy. Side effects attributable to MDL group were sedation(60%)(P<0.01) and dizziness(20%)(P<0.05). In contrast to, headache(20%) of the granisetron group was higher than that of MDL group(P<0.05). Granisetron was effective as MDL therapy for controlling of the acute em esis and nausea induced by cisplatin. But, granisetron was more feasible and safer than MDL therapy.
Key words: Granisetron, Cisplatin, Emesis
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI